

# Financial Tear Sheet

## Corporate Profile

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's Disease (PD).

## Stock Information

BCLI (Common Stock)	
Exchange	NASDAQ CM (US Dollar)
Price	\$4.08
Change (%)	▲ 0.08 (2.00%)
Volume	7,996
52 Week Low	\$2.07
Market Cap	\$75,370,904
Rolling EPS	-0.31
PE Ratio	0
Shares Outstanding	18,842,726
Data as of 11/21/17 10:02 a.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Latest News

November 9, 2017

**NEW PEER REVIEWED PUBLICATION SHOWS THAT BRAINSTORM'S NUROWN® HAS A UNIQUE MIRNA SIGNATURE**

November 2, 2017

**BRAINSTORM STRENGTHENS EXECUTIVE TEAM: APPOINTS EYAL RUBIN AS CHIEF FINANCIAL OFFICER**

October 23, 2017

**BRAINSTORM EXPANDS ITS PATENT PORTFOLIO TO INCLUDE A NEW US PATENT FOR ITS NUROWN® TECHNOLOGY FOR PARKINSON'S DISEASE AND ALS**

## SEC Filings

Filing Date	Form
11/20/17	4
11/20/17	3
11/13/17	4
11/13/17	4

## Upcoming Events

There are currently no events scheduled.

## Primary IR Contact

Michael Rice  
LifeSci Advisors LLC  
E-mail: [mrice@lifesciadvisors.com](mailto:mrice@lifesciadvisors.com)